Background: Doxorubicin can be loaded into preformed liposome by remote loading. Lyophilization of liposomes results in particle size increase and content leakage. Cryoprotectants have been used to improve the stability of liposomal formulations during lyophilization. Here we have developed a formulation kit for liposomal doxorubicin based on lyophilized liposomes incorporating these cryoprotectants.
Materials And Methods: Liposomes compared of egg phosphatidylcholine/cholesterol and containing either glucose or sucrose as a cryoprotectant were prepared by polycarbonate membrane extrusion. These were then loaded with doxorubicin by a pH-gradient-based remote loading procedure either before or after lyophilization and reconstitution. The loading efficiency of DOX was evaluated by gel-filtration chromatography. The effect of lyophilization on the stability of liposomal DOX was also evaluated.
Results: Cryoprotectants were effective in maintaining liposome size distribution but not drug retention during lyophilization. DOX loading efficiency of the reconstituted liposomes was near quantitative and comparable to that of freshly prepared liposomes.
Conclusion: Liposomal doxorubicin can be produced and stored as a lyophilized kit that can be reconstituted without significant changes to critical formulation properties.
Download full-text PDF |
Source |
---|
Liposomal doxorubicin (Dox), a treatment option for recurrent ovarian cancer, often suffers from suboptimal biodistribution and efficacy, which might be addressed with precision drug delivery systems. Here, we introduce a catheter-based endoscopic probe designed for multispectral, quantitative monitoring of light-triggered drug release. This tool utilizes red-light photosensitive porphyrin-phospholipid (PoP), which is encapsulated in liposome bilayers to enhance targeted drug delivery.
View Article and Find Full Text PDFbioRxiv
December 2024
Department of Biomedical, Engineering, Stony Brook University, Stony Brook, NY, 11794, USA.
Liposomal doxorubicin (Dox), a treatment option for recurrent ovarian cancer, often suffers from suboptimal biodistribution and efficacy, which might be addressed with precision drug delivery systems. Here, we introduce a catheter-based endoscopic probe designed for multispectral, quantitative monitoring of light-triggered drug release. This tool utilizes red-light photosensitive porphyrin-phospholipid (PoP), which is encapsulated in liposome bilayers to enhance targeted drug delivery.
View Article and Find Full Text PDFFront Cell Dev Biol
December 2024
Department of Medical Oncology, The First Affiliated Hospital of Anhui Medical University, Hefei, China.
Aim: This study aims to compare the efficiencies and toxicities of pegylated liposomal doxorubicin (PLD) based and epirubicin based chemotherapeutic regimens as neoadjuvant chemotherapy (NAC) for early breast cancer.
Patients And Methods: We retrospectively analyzed 391 patients with stage II-III breast cancer who received NAC in multiple centers. The efficiencies and toxicities of PLD and epirubicin based NAC regimens were compared by using both propensity-score matched (PSM) and unmatched data.
J Obstet Gynaecol India
December 2024
Research Unit, Mangalore Institute of Oncology, Pumpwell, Mangalore, Karnataka 75002 India.
Leuk Lymphoma
January 2025
Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China.
This retrospective study aimed to evaluate the efficacy and safety of PBVD (pegylated liposomal doxorubicin [PLD], bleomycin, vinblastine, and dacarbazine) in the first-line treatment of classical Hodgkin lymphoma (cHL) patients with cardiovascular risk factors. Overall, 84 patients (53 had stage I-II and 31 had stage III-IV disease) received PBVD. The median PLD treatment duration was 16 weeks (interquartile range [IQR]: 8-24) for stage I-II and 24 weeks (IQR: 12-24) for stage III-IV.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!